Oct 5, 2023
In this episode, host Shikha Jain, MD, speaks
with Douglas Micalizzi, MD, and Lecia
Sequist, MD, about adopting novel technologies for early
detection, public perception of prevention screening and more.
• Welcome to another exciting episode of Oncology
Overdrive :58
• About Micalizzi 1:12
• About Sequist 2:26
• The interview 4:06
• Sequist’s background and how she got into the
screening and prevention area of oncology
4:21
• Micalizzi on his chemistry background and how he got
into this space 8:03
• About the evolution of early detection and MGH’s
Cancer Early Detection and Diagnostics Clinic
11:47
• Who is involved in this clinic and how do you handle
a patient’s panic over seeing cancer specialists?
14:30
• Discussion on the New York Times article
Not Everything We Call Cancer Should Be Called Cancer and
nomenclatures surrounding the various cancer stages and types
19:29
• Public perception of screening and the “push” from
people outside of medicine 28:49
• If someone could only listen to the last two minutes
of this episode, what would you want them to take away?
36:31
• How to contact Micalizzi and Sequist
37:51
• Thanks for listening
39:14
Douglas Micalizzi, MD, is a medical oncologist at Massachusetts General Hospital specializing in breast cancer, early cancer detection and hereditary cancer risk.
Lecia V. Sequist, MD, MPH, is currently the Landry Family Professor of Medicine at Harvard Medical School, the Program Director for Cancer Early Detection and Diagnostics at MGH and the leader of the Cancer Risk, Prevention and Early Detection Program at the joint Dana-Farber/Harvard Cancer Center.
We’d love to hear from you! Send your comments/questions to Dr.
Jain at oncologyoverdrive@healio.com.
Follow Healio on X, formerly known as Twitter, and LinkedIn:
@HemOncToday and
https://www.linkedin.com/company/hemonctoday/.
Follow Dr. Jain on X, formerly known as Twitter:
@ShikhaJainMD. Micalizzi and Sequist can be reached through the
Massachusetts General Hospital
Cancer Early Detection and Diagnostics Clinic webpage. Sequist
can also be reached on X, formerly known as Twitter @LeciaSequist.
Disclosures: Jain and Micalizzi report no
relevant financial disclosures. Sequist reports her institution has
received funds related to clinical trials from AstraZeneca, Delfi
Diagnostics and Novartis.